RNAZ
What one share of Transcode Therapeutics holds
Pharmaceutical Preparations
TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers. Our lead therapeutic product candidate is TTX-MC138, an antisense inhibitor of an oncogenic microRNA.
Transcode Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$51.08 |
|---|---|
| Cash and investments | $8.29 |
| Book value | −$27.38 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$10.11 | — | −$2.13 | — | −$14.70 |
| 2021 | — | −$16.24 | $0.60 | −$13.11 | — | $31.62 |
| 2022 | — | −$1,083 | $6.22 | −$977.90 | — | $199.77 |
| 2024 | — | −$1,337 | $1.73 | −$1,064 | — | — |
| 2025 | — | −$52.59 | $0.01 | −$28.31 | — | $11.27 |